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Objective: We correlated selected haematological parameters in Sudanese essential 
thrombocythemia (ET) patients based on their homozygous/heterozygous JAK2V617F genotype, 
as well as the application of thrombotic risk assessment using different thrombotic risk scoring 
models. Methods: In this single-center study, we evaluated 60 patients with ET at the time of the 
diagnosis without any prior treatment. Amplification refractory mutation system-polymerase chain 
reaction (ARMS-PCR) technique was used to determine JAK2V617F mutation status. Complete 
blood count was evaluated using the Sysmex analyzer.  Furthermore, the thrombotic risk 
assessment of ET patients using different thrombotic risk scoring models was applied. Results: 
The JAK2V617F mutation was detected in 29/60 patients (48.3%), of whom 23 (38.3% of total) 
were heterozygous and 6 (10.0%) were homozygous.  Compeered to JAK2 wild-type or JAK2 
heterozygous patients, JAK2 homozygous patients for JAK2V617F mutation were associated with 
older age(p < 0.05), significantly higher mean leukocytes count (P =0.001), significantly lower Hb 
concentration (p < 0.05), and splenomegaly (p < 0.05), while the mean of the platelet counts was 
slightly higher, although not reached a significant level. We also found two patients who developed 
thrombotic events throughout follow-up and were initially classified as a low-risk category in the 
traditional classification. One of them with age < 60 years, hypertension, and JAK2 homozygosity 
but without thrombosis history, was allocated in a high-risk category by IPSET-t and r- IPSET-t 
scores. The second patient was stratified in a low-risk category by all scoring models with age < 
60 years, hypertension, leukocytosis, unmutated JAK2, and without a history of thrombosis. 
Conclusions: The JAK2 V617F homozygosity correlated with older age, higher leukocyte count, 
lower Hb concentration, and a higher risk of thrombosis in Sudanese ET patients. Evaluation of 
hypertension and identification of JAK2 V617F homozygosity at diagnosis of ET might give the 
clinician more meaningful prognostic information and so improve the therapeutic management.  
Keyword: Essential thrombocythemia; JAK2 mutation; JAK2 V617F homozygosity; Thrombotic 
risk 
